Mechanisms of drug resistance in Mycobacterium tuberculosis

Current Topics in Microbiology and Immunology

Volumn 215, Issue , 1996, Pages 49-69

  Heym, B ^a   Philipp, W ^b   Cole, S T ^b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; ISONICOTINIC ACID; KANAMYCIN; NICOTINIC ACID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT; VIOMYCIN;

ANTIBIOTIC RESISTANCE; CHROMOSOMAL LOCALIZATION; DRUG MECHANISM; GENE LOCATION; HUMAN; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0029739927     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-80166-2_3     Document Type: Review

References (133)

1. American Thoracic Society (1986) Treatment of tuberculosis and tuberculous infection in adults and children. Am Rev Respir Dis 134: 355-363
2. American Thoracic Society (1992) Control of tuberculosis in the United States. Am Rev Respir Dis 146: 1623-1633
3. Association Française Raoul Follereau, the STD3 Program of the European Community (Grant TS3*CT93*0243) and the National Institute of Allergy and Infectious Diseases (A137015)
4. Ayvazian LF (1993) History of tuberculosis. In Reichman LB, Hershfield ES (eds) tuberculosis-a comprehensive international approach Dekker, New York, pp 1-20
5. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR Jr (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis Science 263: 227-230
6. Barclay WR, Ebert RH, Koch-Weser D (1953) Mode of action of isoniazid, part I. Am Rev Tuberc 67: 490-496
7. Barnes PF, Bloch AB, Davidson PT, Snider DE (1991) Tuberculosis in patients with human immunodeficiency virus infection N Engl J Med 324 1644-1650
8. Beggs WH, Andrews FA (1976) Inhibition of dihydrostrepomycin binding to Mycobacterium smegmatis by monovalent and divalent cation salts. Antimicrob Agents Chemother 9: 393-396
9. Benveniste R, Davies J (1973) Mechanisms of antibiotic resistance in bacteria. Annu Rev Biochem 42: 471-506
10. Bergler H, Hōgenauer G, Turnowsky F (1992) Sequences of the envM gene and two mutated allels in Escherichia coli J Gen Microbiol 138: 2093-2100
11. Bernstein J, Lott WA, Steinberg BA, Yale HL (1952) Chemotherapy of experimental tuberculosis. Am Rev Tuberc 65. 357-354
12. Bloom BR, Murray JL (1992) Tuberculosis, commentary on a reemergent kilier. Science 257. 1055-1064
13. Böttger EC (1994) Resistance to drugs targeting protein synthesis in mycobacteria. Trends Microbiol 2: 416-421
14. Bryan LE, van den Elzen HM (1977) Effects of membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: a model for entry of streptomycin and gentamicin in susceptible and resistant bacteria. Antimicrob Agents Chemother 12. 163-177
15. Buck M, Schnitzer RJ (1952) The development of drug resistance of M. tuberculosis to isonicotinic acid hydrazide. Am Rev Tub 65: 759-760
16. Burgess RR, Erickson B, Gentry D, Gribstov M, Hager D, Lesley S, Strickland M, Thompson N (1987) Bacterial RNA polymerase subunits and genes. RNA polymerase and the regulation of transcrption. Elsevier, New York, pp 3-15
17. Canetti G, Grosset J (1961) Teneur des souches sauvages de Mycobacterium tuberculosis en variants résistants à l'isoniazide et en variants résistants à la streptomycine sur milieu de Loewenstein-Jensen. Ann Inst Pasteur 101: 28
18. Centers for Disease Control (1993) Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the advisory council for the elimination of tuberculosis. MMWR 42 (RR-7): 1-8
19. Claiborne A, Fridovitch I (1979) Purification of the o-dianisidine peroxidase from Escherichia coli. J Biol Chem 254: 4245-4252
20. Conn ML, Kovitz C, Oda U, Middlebrook G (1954) Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activity, and pathogenic properties of isonsazid-resistant mutants. Am Rev Tuberc 70: 641-669
21. Cole ST (1994) Drug resistance mechanisms employed by Mycobacterium tuberculosis. Trends Microbiol 2: 412-415
22. Cole ST, Smith DR (1994) Toward mapping and sequencing the genome of Mycobacterium tuberculosis. In: Bloom BR (ed) Tuberculosis: pathogenesis, protection, and control. American Society of Microbiology, Washington DC, pp 227-238
23. Collins CH, Uttley AHC (1985) In vitro susceptibility of mycobacteria to ciprofloxacin. J Antmicrob Chemother 16: 575-580
24. Cooksey RC, Crawford JT, Jacobs WR, Shinnick TM (1993) A rapid method for screening antimicrobial agents for activities against a strain of Mycobacterium tuberculosis expressing firefly luciferase. Antimicrob Agent Chemother 37: 1348-1352
25. Crawford JT, Bates JH (1979) Isolation of plasmids from mycobacteria. Infect Immun 24(3): 979-981
26. Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Hopewell PC (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 326: 231-235
27. Davidson LA, Takayama K (1979) Isoniazid inhibition of the synthesis of monounsaturated long-chain fatty acids in Mycobacterium tuberculosis H37Ra. Antimicrob Agent Chemother 16. 104-105
28. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD (1992) An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326. 1514-1521
29. Falkinham JO III, Crawford JT (1994) Plasmids In: Bloom BR (ed) Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington DC, pp 185-198
30. Fenlon CH, Cynamon MH (1986) Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agent Chemother 29: 386-388
31. Finken M, Kirschner P, Meier A, Wrede A, Bòttger EC (1993) Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot Mol Microbiol 9: 1239-1246
32. Forbes M, Kuck NA, Peets EA (1965) Effect of ethambutol on nucleic acid metabolism in Mycobacterium smegmatis and its reversal by polyamines and divalent cations. J Bacteriol 89: 1299-1305
33. Fox HH (1951) Synthetic tuberculostatics show promise Chem Eng News 29: 3963-3964
34. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328. 521-526
35. Funatsu G, Wittmann HG (1975) Location of amino acid replacements in protein S12 isolated from Escherichia coli mutants resistant to streptomycin. J Mol Biol 68: 547-550
36. Gale EF, Cundliffe E, Reynolds PE, Richmond MH, Waring MJ (1981) The moelcular basis of antibiotic action Wiley, London
37. Galili H, Fromm H, Aviv D, Edelman M, Galun E (1989) Ribosomal protein S12 as a site of streptomycin resistance in Nicotinia chloroplasts. Mol Gen Genet 218: 289-292
38. Garvin RT, Biswas DK, Gorini L (1974) The effects of streptomycin or dihydrostreptomycin binding to 16S RNA or to 30S ribosomal subunits. Proc Natl Acad Sci USA 71: 3814-3818
39. Goble M, Madsen LA, Waste D, Ackerson L, Horsburgh R (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328: 527-532
40. Goswitz JJ, Willard KE, Fasching CE, Perterson LR (1992) Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin resistant Staphylococcus aureus: analysis by polymerase chain reaction and direct DNA sequencing. Antimicrob Agents Chemother, 36: 1166-1169
41. Grosset J, Levantis S (1983) Adverse effects of rifampin. Rev Infect Dis 5 [Suppl 3]: S440-S446
42. Grosset JH (1989) Present status of chemotherapy for tuberculosis. Rev Infect Dis 11 [Suppl 2]: S347-S352
43. Heifets L (1988) Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis 137: 1217-1222
44. Herman RP, Weber MM (1980) isoniazid interaction with tyrosine as a possible mode of action of the drug in mycobacteria. Antimicrob Agents Chemother 17: 170-178
45. Hermans PWM, van Soolingen D, van Embden JDA (1992) Characterization of a major polymorphic tandem repeat in Mycobacterium tuberculosis and its potential use in the epidemiology of Mycobacterium kansasii and Mycobacterium gordonae J Bacteriol 174: 4157-4156
46. Heym B, Zhang Y, Poulet S, Young D, Cole ST (1993) Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis. J Bacteriol 175; 4255-4259
47. Heym B, Honoré N, Truffot-Pernot C, Banerjee A, Schurra C, Jacobs WR Jr, van Embden JDA, Grosset JH, Cole ST (1994a) The implications of multidrug-resistance for the future of short course chemotherapy of tuberculosis: a molecular study. Lancet 344: 293-298
48. Heym B, Alzari PM, Honoré N, Cole ST (1994b) Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis Mol Microbiol 15: 235-245
49. Honoré N, Cole ST (1993) The moelcular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 37: 414-418
50. Honoré N, Cole ST (1994) Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 38: 238-242
51. Honoré N, Bergh S, Chanteau S, Doucet-Populaire F, Eiglmaier K, Garnier T, Georges C, Launois P, Limpaiboon T, Newton S, Niang K, del Portillo P, Ramesh GR, Reddi P, Ridel PR, Sittisombut N, WU-Hunter S, Cole ST (1993) Nucleotide Sequence of the first cosmid from the Mycobacterium leprae genome project: structure and function of the Rrf-Str regions. Mol Microbiol 7: 207-214
52. Hooper DC, Wolfson JS (1993) Mechanisms of quinolone action and bacterial killing. Quinolone antimicrobial Agents American Society for Microbiology, Washington DC, pp 53-76
53. Hopewell PC (1994) The cure: organization and administration of therapy for tuberculosis In: Porter JDH, McAdam KPW (eds) Tuberculosis - back to the future. Wiley, Chichester, pp 99-120
54. Imboden P, Cole S, Bodmer T, Telenti A (1993) Detection of Rifampm Resistance Mutations in Mycobacterium tuberculosis and M leprae In. Persing DH, Smith TF, Tenover FC, White TJ (eds) Diagnostic moelcular microbiology Principles and applications. American Society for Microbiology, Washington DC, pp 519-526
55. Iseman MD (1994) Evolution of drug-resistant tuberculosis a tale of two species Proc Natl Acad Sci USA 91: 2428-2429
56. Iseman MD, Cohn DL, Sbarbaro JA (1993) Directly observed treatment of tuberculosis N Engl J Med 328 576-578
57. Jacobs WR Jr, Tuckman M, Bloom BR (1987) Introduction of foreign DNA into mycobacteria using a shuttle plasmid Nature 327: 532-535
58. Jacobs WR Jr, Barłetta RG, Udani R, Chan J, Kalkut G, Sosne G, Kieser T, Sarkis GJ, Hatfull GF, Bloom BR (1993) Rapid assessment of drug susceptibilities by means of luciferase reporter phages Science 260: 819-822
59. Jarlier V, Nikaido H (1990) Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J Bacteriol 172: 1418-1423
60. Jin DJ, Gross CA (1989) Characterization of the pleiotropic phenotypes of rifampin-resistant rpoB mutants of Escherichia coli. J Bacteriol 171: 5229-5231
61. Johnsson K, Schultz PG (1994) Mechanistic studies of the oxidation of isoniazid by the catalase-peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 116: 7425-7426
62. Kanner BI, Gutnick DL (1972) Use of neomycin in the isolation of mutants blocked in energy conservation in Escherichia coli J Bactenol 111: 287-289
63. Kapur V, Hamrick MR, LI L-L, Plikaytis BB, Shinnick TM, Telenti A, Jacobs WR, Banerjee A, Cole ST, Yam WC, Clarridge JE, Kreiswirth BN, Musser JM (1994) Application of automated DNA sequencing strategies to problems of Mycobacterium diagnostics: speciation by characterization of polymorphisms in the gene (hsp65) encoding a 65-kilodalton heat shock protein, and a rapid an unambiguous identification of mutations associated with antibiotic resistance in Mycobacterium tuberculosis. JAMA (submitted)
64. Kempsell KE, Ji Y-E, Estrada-G ICE, Colston MJ, Cox RA (1992) The Nucleotide Sequence of the Promoter, 16S rRNA and Spacer Region of the Ribosomal RNA Operon of Mycobacterium tuberculosis and Comparison with Mycobacterium leprae Precursor rRNA. J Gen Microbiol 138: 1717-1727
65. Kilburn JO, Greenberg J (1977) Effect of ethambutol on the viable cell count in Mycobacterium smegmatis. Antimicrob Agent Chemother 11: 534-540
66. Konno K, Feldmann FM, McDermott W (1967) Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 95: 461-469
67. Krüger-Thiemer E, Kroger H, Nestler HJ, Seydel JK (1975) Bakteriologische Grundlagen der Chemotherapie der Tuberkulose. Mykobakterien und mykobakterielle Krankheiten. Fischer, Jena, pp 251-288
68. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B (1993) Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agent Chemother 37: 407-413
69. Loewen PC, Switala J, Triggs-Raine BL (1985) Catalases HPI and HPII in Escherichia coli are induced independently. Arch Biochem Biophys 243: 144-149
70. Loprasert S, Negoro S, Okada H (1988) Thermostable peroxidase from Bacillus stearothermophilus. J Gen Microbiol 134: 1971-1976
71. Mackaness GB (1956) The intracellular activation of pyrazinamide and nicotinamide. Am Rev Tuberc Pulm Dis 74: 718-728
72. Martin C, Ranes M, Gicquel B (1990) Plasmids, antibiotic resistance, and mobile genetic elements in mycobacteria In: McFadden J (ed) The molecular biology of the mycobacteria, Surrey University Press, London, pp 120-138
73. McDermott W, Tompsett R (1954) Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 71. 748-754
74. Meier A, Kirschner P, Bange F-C, Vogel U, Böttger EC (1994) Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance. Antimicrob Agents Chemother 38: 228-233
75. Meyer H, Mally J (1912) Über Hydrazindenvate der Pyridincarbonsauren. Monatshefte Chem 33: 393-414
76. Middlebrook G (1952) Sterilization of tubercle bacilli by isonicotinic acid hydrazide and the incidence of variants resistant to the drug in vitro. Am Rev Tuberc 65. 765-767
77. Miller LP, Crawford JT, Shinnick TM (1994) The rpoB gene of Mycobacterium tuberculosis Antimicrob Agent Chemother 38. 805-811
78. Mitchison DA (1950) Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis Thorax 5: 144-161
79. Mitchison DA (1951) The segregation of streptomycin-resistant variants of Mycobacterium tuberculosis into groups with characteristic levels of resistance J Gen Microbiol 5: 596-604
80. Moazed D, Nouer HF (1987) Interaction of antibiotics with functional sites in 16S ribosomal RNA Nature 327: 389-394
81. Montandon P-E, Wagner R, Stutz E (1986) E coli ribosomes with a C912 to U base change in the 16S rRNA are streptomycin resistant. EMBO J 5 3705-3708
82. Morris SL, Nair J, Rouse DA (1992) The catalase-peroxidase of Mycobacterium intracellulare. nucleotide sequence analysis and expression in Escherichia coli J Gen Microbiol 138: 2363-2370
83. Murray CJL, Styblo K, Rouillon A (1990) Tuberculosis in developing countries burden, intervention and cost Bull Int Un Tuberc 65: 6-24
84. Nair J, Rouse DA, Bai G-H, Morris SL (1993) The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Microbiol 10: 521-527
85. Noller H (1984) Structure of ribosomal RNA. Annu Rev Biochem 53: 119-162
86. O'Brien RJ (1993) The treatment of tuberculosis. In: Reichman LB, Hershfield ES (eds) Tuberculosis - a comprehensive international approach. Dekker, New York, pp 207-240
87. Oram M, Fisher LM (1991) 4-Quinolone resistance mutation in the DNA gyrase of Escherichia coli clinical isolates identified using the polymerase chain reaction Antimicrob Agent Chemother 35: 387-389
88. Ovchinnikov YA, Monastyrskaya GS, Gunev SO, Kalinina NF, Sverdlof ED, Gragerov AI, Bass IA, Kiver IF, Moiseyeva EP, Igumnov VN, Mindlin SZ, Nikiforov VG, Khesin RP (1983) RNA polymerase rifampicin resistance mutations in Escherichia coli: sequence changes and dominance Mol Gen Genet 190: 344-348
89. Peizer LR, Widelock D (1955) The correlation of rate of catalase activity, Guinea pig virulence, and isoniazid resistance of tubercle bacilli from specimens of patients under isoniazid therapy. Am Rev Respir Dis 72: 246-251
90. Pessolani MCV, Smith DR, Rivoire B, McComnick J, Hefta SA, Cole ST, Brennan P (1994) Purification, characterization, gene sequence and significance of a bacterioferritin from Mycobacterium leprae. J Exp Med 180: 319-327
91. Rastogi N, Goh KS (1991) In vitro activity of the new difluorinated quinolone sparfloxacin (AT -4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agent Chemother 35: 759-764
92. Rosner JL (1993) An alternative to Mycobacterium tuberculosis for studying isoniazid resistance: oxyR regulon mutants of Escherichia coli Antimicrob Agent Chemother 37: 2251-2253
93. Rosner JL, Storz G (1994) Peroxides and isoniazid-susceptibility of Escherichia coli and Mycobacterium smegmatis. Antimicrob Agent Chemother 38: 1829-1833
94. Saaren M, Khuller GK (1990) Cell wall and membrane changes associated with ethambutol resistance in Mycobacterium tuberculosis H37Ra. Antimicrob Agent Chemother 34: 1773-1776
95. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA (1988) Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase. Science 239:487-491
96. Schwartz WS, Moyer RE (1954) The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid. Am Rev Tuberc 70: 413-429
97. Sewell DL, Rashad AL, Rourke WJ, Poor SL, McCarthy JAC, Pfaller MA (1993) Comparison of the septi-chek AFB and BACTEC systems and conventional culture for recovery of mycobacteria. J Clin Microbiol 31: 2689-2691
98. Seydel JK, Schaper K-J, Wempe E, Cordes HP (1976) Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type. J Med Chem 19 483-491
99. Shoeb HA, Bowman BU Jr, Ottolenghi AC, Merola AJ (1985) Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra. Antimicrob Agent Chemother 27: 404-407
100. Stive G, Valero-Guillen P, Quemard A, Dupont M, Daffe M, Laneelle G (1993) Ethambutol inhibition of glucose metabolism in mycobacteria: a possible target of the drug. Antimicrob Agent Chemother 37: 1536-1538
101. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E, Sierra MF, Schoolnik GK (1993) Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 328: 1137-1144
102. Smith DW, Tee TW, Baird C, Krishnapillai V (1991) Pseudomonad replication origins: a paradigm for bacterial origins? Mol Microbio 5: 2581-2587
103. Snider DE Jr, Roper WL (1992) The new tuberculosis. N Engl J Med 326: 703-705
104. Snider DE Jr, Good RC, Kilburn JO, Laskowski LF Jr, Lusk RH, Marr JH, Reggiardo Z, Middlebrook G (1981) Rapid drug-susceptibility testing of Mycobacterium tuberculosis. Am Rev Respir Dis 123: 402-406
105. Steenken W Jr, Meade GM, Wolinsky E, Coates EO Jr (1952) Demonstration of increased drug resistance of tubercle bacilli from patients treated with hydrazines of isonicotinic acid. Am Rev Tuberc 65: 754-758
106. Steenken W Jr, Wolinsky E, Smith MM, Montalbine V (1957) Further observations on pyrazinamide alone and in combination with other drugs in experimental tuberculose. Am Rev Tub Pulm Dis 76: 643-659
107. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, Allen RD, Gluck SL, Heuser J, Russell DG (1994) Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton ATPase. Science 263: 678-681
108. Takayama K, Kilburn JO (1989) Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis Antimicrob Agent Chemother 33: 1493-1499
109. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreisworth B, Cole S, Telenti A, Jacobs WR (1994) Cloning and nucleotide sequence of the Mycobacterium tuberculosis gyrA and gyrB genes, and characterization of quinolone resistance mutations Antimicrob Agents Chemother 38: 773-780
110. Tarshis MS, Weed WA Jr (1953) Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 67. 391-395
111. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole ST, Colston MJ, Matter L, Schopfer K, Bodmer T (1993a) Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341: 647-650
112. Telenti A, Imboden P, Marchesi F, Schmidheini T, Bodmer T (1993b) Direct, automated detection of rifampicin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 37: 2054-2058
113. Tenover FC, Crawford JT, Huebner RE, Geiter LJ, Horsburgh CR, Good RC (1993) The resurgence of tuberculosis, is your laboratory ready? J Clin Mircobiol 31: 767-770
114. Trias J, Benz R (1993) Characterization of the channel formed by the mycobacterial porin in lipid bilayer membranes. J Biol Chem 268: 6234-6240.
115. Triggs-Raine BL, Doble BW, Mulvey MR, Sorby PA, Loewen PC (1988) Nucleotide sequence of katG. encoding catalase HPI of Escherichia coli. J Bact 1970: 4415-4419
116. Trimble KA, Clark RB, Sanders WE Jr, Frankel JW, Cacciatore R, Valdez H (1987) Activity of ciprofloxacin against mycobacteria in vitro: comparison of BACTEC and macrobroth dilution methods. J Antimtcrob Chemother 19: 617-622
117. Tsukarnura M, Tsukamura S (1963) Isotopic studies on the effect of isoniazid on protein synthesis of mycobacteria. Jpn J Tuberc 11 14-17
118. Tsukamura M, Hasimoto M, Noda Y (1958) Transformation of isoniazid and streptomycin resistance in Mycobacterium avium by the desoxyribonucleate derived from isoniazid- and streptomycin-double-resistant cultures. Am Rev Respir Dis 81: 403-406
119. Turnowsky F, Fuchs K, Jeschek C, Högenauer G (1989) envM genes of Salmonella typhimurium and Escherichia coli. J Bacteriol 171: 6555-6565
120. Wallace BJ, Davis BD (1973) Cyclic blockade of initiation sites by streptomycin-damaged ribosomes in Escherichia coli: an explanation for dominance of sensitivity. J Mol Biol 75: 377-390
121. Wang JC (1985) DNA topoisomerases Annu Rev Biochem 54: 665-697
122. Wehrli W (1983) Rifampin: mechanisms of action and resistance. Rev Infect Dis 5: S407-S411
123. Weisblum B, Davies J (1968) Antibiotic inhibitors of the bacterial ribosome. Bacteriol Rev 32. 493-528
124. Wimpenny JWT (1967) Effect of isoniazid on biosynthesis in Mycobacterium Tuberculosis var bovis BCG. J Gen Microbiol 47: 379-388
125. Winder FG (1982) Effect of isoniazid on biosynthesis in Mycobacterium tuberculosis var. bovis BCG. J Gen Microbiol 47: 379-388
126. Witzig RS, Franzblau SG (1993) Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agent Chemother 37. 1997-1999
127. Wolfson JS, Hooper DC (1989) Bacterial resistance to quinolones Rev Infect Dis 11. S960-S968
128. Yeager RL, Munroe WGC, Dessau FI (1952) Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 65: 523-534
129. Yew WW, Kwan Sy-L, Ma WK, Khin MA, Chau PY (1990) In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 26 227-236
130. Yoshida H, Bogaki M, Nakamura M, Nakamura S (1990) Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agent Chemother 34. 1271-1272
131. Youatt J (1969) A review of the action of isoniazid Am Rev Respir Dis 99. 729-749
132. Zhang Y, Heym B, Allen B, Young D, Cole S (1992) The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis Nature 358 591-593
133. Zhang Y, Garbe T and Young D (1993) Transformation with katG restores tsoniazid-sensitivity in Mycobacterium tuberculosis isloates resistant to a range of drug concentrations Mol Microbiol 8: 521-524